ReviewHuman vaccines & immunotherapeutics2014
Recent progress in adjuvant discovery for peptide-based subunit vaccines.
Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability.PloS one · 2016Pooled it
- Toxicological evaluation of a synthetic QS-21 adjuvant in a tuberculosis vaccine candidate-Demonstrating safety and immunological equivalence to natural reference.Human vaccines & immunotherapeutics · 2026Article
- Article
- In silico design of a multi-epitope vaccine targeting DENV-1 and DENV-3.Scientific reports · 2026Article
- Exploratory Evaluation of Peptide-Based Immunization Targeting Fusion Glycoprotein-Derived Epitopes of Nipah Virus in Murine Model.Vaccines · 2026Article
- Design of a novel epitope-based tetravalent subunit vaccine against dengue virus: An immunoinformatic approach.PloS one · 2026Article
- Article
- Development of a Broad-Spectrum Pan-Mpox Vaccine via Immunoinformatic Approaches.International journal of molecular sciences · 2025Article
- Advances in nanotechnology-enabled adjuvants for peptide-based cancer vaccines.Nano research · 2025Article
- Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.Signal transduction and targeted therapy · 2025Review
- Lipoprotein Signal Peptide as Adjuvants: Leveraging Lipobox-Driven TLR2 Activation in Modern Vaccine Design.Vaccines · 2025Review
- Development and protective efficacy of multi-epitope vaccine FL46 against cystic echinococcosis.Frontiers in immunology · 2025Article
- From bark to bench: innovations in QS-21 adjuvant characterization and manufacturing.Frontiers in immunology · 2025Review
- Peptide vaccines: an innovative therapeutic approach against antibiotic-resistant bacterial infections.Frontiers in immunology · 2025Review
- Polymer Nanoparticles Advancements for Gynecological Cancers.International journal of nanomedicine · 2025Review
- In silico designing of novel epitope-based peptide vaccines against HIV-1.Biotechnology letters · 2024Article
- Review
- Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine.PLoS computational biology · 2024Article
- Research progress on emulsion vaccine adjuvants.Heliyon · 2024Review
- Immunomodulatory Peptides as Vaccine Adjuvants and Antimicrobial Agents.Pharmaceuticals (Basel, Switzerland) · 2024Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide-based subunit vaccines are of great interest in modern immunotherapy as they are safe, easy to produce and well defined. However, peptide antigens produce a relatively weak immune response, and thus require the use of immunostimulants (adjuvants) for optimal efficacy. Developing a safe and effective adjuvant remains a challenge for peptide-based vaccine design. Recent advances in immunology have allowed researchers to have a better understanding of the immunological implication of related diseases, which facilitates more rational design of adjuvant systems. Understanding the molecular structure of the adjuvants allows the establishment of their structure-activity relationships which is useful for the development of next-generation adjuvants. This review summarizes the current state of adjuvants development in the field of synthetic peptide-based vaccines. The structural, chemical and biological properties of adjuvants associated with their immunomodulatory effects are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.